Upcoming Dividend • Jun 25
Upcoming dividend of €1.45 per share Eligible shareholders must have bought the stock before 02 July 2026. Payment date: 06 July 2026. Payout ratio is a comfortable 8.0% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.6%). Declared Dividend • May 31
Dividend of €1.45 announced Dividend of €1.45 is the same as last year. Ex-date: 2nd July 2026 Payment date: 6th July 2026 Dividend yield will be 0.4%, which is lower than the industry average of 2.4%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 13%. Tillkännagivande • May 25
Virbac SA, Annual General Meeting, Jun 29, 2026 Virbac SA, Annual General Meeting, Jun 29, 2026. Location: 13e rue lid, carros France Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Olivier Charmeil was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Mar 18
Virbac Sa Proposes Dividend for the Fiscal Year 2025 Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2025 fiscal year. Tillkännagivande • Jan 20
Virbac SA Provides Earnings Guidance for the Year 2026 Virbac SA provided earnings guidance for the year 2026. 2026 guidance: (incl. Thyronorm acquisition impact): revenue growth expected to be between 5.5% and 7.5% at constant rates and scope. Tillkännagivande • Dec 17
Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million. Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million on December 16, 2025. The transaction is expected to be accretive to Virbac Group sales growth and EBITDA margin from year 1. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) before being gradually taken over by Virbac.
Thyronorm has in-market sales of approximately €27 million.
Virbac SA (ENXTPA:VIRP) completed the acquisition of Thyronorm from Norbrook Laboratories Limited on December 16, 2025. Tillkännagivande • Dec 08
Virbac SA to Report First Half, 2026 Results on Sep 17, 2026 Virbac SA announced that they will report first half, 2026 results on Sep 17, 2026 Tillkännagivande • Oct 17
Virbac SA Updates Revenue Guidance for the Year 2025 Virbac SA updated revenue guidance for the year 2025. For the year, the company expects sales momentum observed in the third quarter, revenue growth at constant exchange rates and scope is now expected to be between 5.5% and 7.5% (against 4 to 6% before). Tillkännagivande • Sep 13
Virbac Sa Confirms Earnings Guidance for the Year 2025 Virbac SA confirmed earnings guidance for the year 2025. For the year, the company confirms outlook for revenue growth at constant rates and scope of between 4% and 6%. The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025. Tillkännagivande • Jun 21
Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025 Virbac SA announced the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25
years of extensive international experience, particularly in consumer health, consumer goods, and pharmaceuticals. His professional journey is marked by roles of increasing responsibility in Europe, Asia, and Latin America, first at Ernst & Young, then at Reckitt Benckiser and Novartis Consumer Healthcare. For the past eleven years, he has been part of the executive committee that oversaw the merger of Boehringer Ingelheim's and Sanofi's
Consumer Healthcare businesses. During this time, he led key regions and served as chief growth officer. For the last three years, he has held the position of senior vice president, region head for Europe and Latin America, a region generating close to 3 billion euros in revenue. He was also part of the leadership team that successfully completed the spin-off of Opella. Paul is a recognized leader for his ability to develop diverse and agile teams, lead growth and learning-oriented cultures. He has proven his ability in building collective visions and leading successful transformations in operational roles, to deliver superior performance. Tillkännagivande • May 13
Virbac SA, Annual General Meeting, Jun 19, 2025 Virbac SA, Annual General Meeting, Jun 19, 2025. Location: 13e rue lid, carros France Tillkännagivande • Jan 17
Virbac SA Provides Revenue Guidance for the Year 2025 Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%. Board Change • Dec 30
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Olivier Charmeil was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Tillkännagivande • Dec 04
Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. on December 2, 2024.
Virbac SA (ENXTPA:VIRP) completed the acquisition of Mopsan Veteriner Urunleri A.S. on December 2, 2024. Tillkännagivande • Jul 17
Virbac SA Revises Earnings Guidance for the Fiscal Year 2024 Virbac SA revised earnings guidance for the fiscal year 2024. For the year, The company anticipates revenue growth between 7% and 9%. Tillkännagivande • Jul 08
Virbac Sa Announces Chief Executive Officer Changes Virbac SA announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Sébastien Huron, while the appointments and compensation committee recruits the next chief executive officer. Backed by the board of directors, Habib will be able to count on the full support of the Group executive committee in executing the roadmap of our Virbac 2030 project. About Habib Ramdani: Habib Ramdani is a graduate of the École Centrale de Paris. He started his career in 1999 as a strategy consultant at the Boston Consulting Group (BCG). He joined the pharmaceutical company Ipsen in 2002 where he quickly became Group Strategic Planning director. He was then appointed Group Controller and oversaw the Group's Management Control department as well as Ipsen's Group Financial Accounting and Consolidation department before taking over the Finance and Strategy department of the North American subsidiaries while based in New Jersey, USA. He joined the Virbac Group in 2016 as chief financial officer and member of the executive board, before being appointed deputy chief executive officer and member of the Group executive committee on December 15, 2020. Upcoming Dividend • Jun 18
Upcoming dividend of €1.32 per share Eligible shareholders must have bought the stock before 25 June 2024. Payment date: 27 June 2024. Payout ratio is a comfortable 9.2% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.2%). Declared Dividend • May 27
Dividend of €1.32 announced Dividend of €1.32 is the same as last year. Ex-date: 25th June 2024 Payment date: 27th June 2024 Dividend yield will be 0.4%, which is lower than the industry average of 2.4%. Payout Ratios Payout ratio: 9%. Cash payout ratio: 19%. Reported Earnings • Apr 28
Full year 2023 earnings released: EPS: €14.40 (vs €14.43 in FY 2022) Full year 2023 results: EPS: €14.40 (down from €14.43 in FY 2022). Revenue: €1.25b (up 2.5% from FY 2022). Net income: €121.3m (flat on FY 2022). Profit margin: 9.7% (in line with FY 2022). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Tillkännagivande • Apr 03
Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591). Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor.
Virbac SA (ENXTPA:VIRP) completed the acquisition of Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) on April 1, 2024. Reported Earnings • Mar 20
Full year 2023 earnings released: EPS: €14.40 (vs €14.44 in FY 2022) Full year 2023 results: EPS: €14.40 (down from €14.44 in FY 2022). Revenue: €1.25b (up 2.5% from FY 2022). Net income: €121.3m (flat on FY 2022). Profit margin: 9.7% (in line with FY 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Tillkännagivande • Mar 08
Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million. Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor. Tillkännagivande • Jan 18
Virbac SA Provides Earnings Guidance for the Year 2024 Virbac SA provided earnings guidance for the year 2024. For the year 2024, the company confirm a revenue growth target between 4% and 6% at constant rates and scope, as well as a ratio of "current operating income before amortisation of assets resulting from acquisitions” to “revenue” around 15% at constant exchange rates. As announced in previous communications, this level of profitability takes into account a deliberate further acceleration in R&D investments, representing almost +0.5 points as a percentage of revenue compared with 2023. Buying Opportunity • Dec 28
Now 21% undervalued Over the last 90 days, the stock is up 43%. The fair value is estimated to be €440, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 4.6% per annum. Earnings is also forecast to grow by 8.6% per annum over the same time period. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €343, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €433 per share. Tillkännagivande • Oct 11
Virbac SA (ENXTPA:VIRP) signed an agreement to acquire Globion India Private Limited from Suguna Foods Private Limited and Lohmann Animal Health GmbH. Virbac SA (ENXTPA:VIRP) signed an agreement to acquire Globion India Private Limited from Suguna Foods Private Limited and Lohmann Animal Health GmbH on October 9, 2023. Globion reported annual revenues of €12 million. Veda Corporate Advisors acted as financial advisor to Globion and Suguna. Reported Earnings • Oct 09
First half 2023 earnings released: EPS: €8.86 (vs €9.18 in 1H 2022) First half 2023 results: EPS: €8.86 (down from €9.18 in 1H 2022). Revenue: €610.5m (down 1.0% from 1H 2022). Net income: €74.8m (down 3.6% from 1H 2022). Profit margin: 12% (in line with 1H 2022). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Sep 29
Virbac SA Confirms Revenue Forecasts for the Year 2023 Virbac SA confirmed revised revenue forecasts for the year 2023. The company confirms revised forecasts with revenue growth at constant rates and scope expected in a range between 0% and 4%. Buying Opportunity • Aug 01
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 6.1%. The fair value is estimated to be €355, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 17%. For the next 3 years, revenue is forecast to grow by 3.7% per annum. Earnings is also forecast to grow by 6.7% per annum over the same time period. Buying Opportunity • Jun 27
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 9.2%. The fair value is estimated to be €340, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 17%. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings is also forecast to grow by 8.1% per annum over the same time period. Upcoming Dividend • Jun 19
Upcoming dividend of €1.32 per share at 0.5% yield Eligible shareholders must have bought the stock before 26 June 2023. Payment date: 28 June 2023. Payout ratio is a comfortable 9.1% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.5%). Reported Earnings • Mar 25
Full year 2022 earnings released: EPS: €14.44 (vs €13.40 in FY 2021) Full year 2022 results: EPS: €14.44 (up from €13.40 in FY 2021). Revenue: €1.22b (up 14% from FY 2021). Net income: €122.0m (up 7.8% from FY 2021). Profit margin: 10.0% (in line with FY 2021). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 22% per year. Tillkännagivande • Dec 15
Virbac SA to Report First Half, 2023 Results on Sep 14, 2023 Virbac SA announced that they will report first half, 2023 results on Sep 14, 2023 Valuation Update With 7 Day Price Move • Oct 22
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €248, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 17% over the past three years. Tillkännagivande • Oct 19
Virbac SA Provides Revenue Guidance for the Year 2022 Virbac SA provided revenue guidance for the year 2022. The company anticipates in 2022 a revenue growth at constant rates and perimeter is now expected to be in a range of between 6% and 9%. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €271, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 28% over the past three years. Reported Earnings • Sep 18
First half 2022 earnings released: EPS: €9.18 (vs €8.54 in 1H 2021) First half 2022 results: EPS: €9.18 (up from €8.54 in 1H 2021). Revenue: €616.4m (up 16% from 1H 2021). Net income: €77.5m (up 7.7% from 1H 2021). Profit margin: 13% (down from 14% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jun 17
Upcoming dividend of €1.25 per share Eligible shareholders must have bought the stock before 24 June 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 9.3% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (2.8%). Reported Earnings • May 02
Full year 2021 earnings released: EPS: €13.40 (vs €16.13 in FY 2020) Full year 2021 results: EPS: €13.40 (down from €16.13 in FY 2020). Revenue: €1.06b (up 14% from FY 2020). Net income: €113.2m (down 17% from FY 2020). Profit margin: 11% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.9%, compared to a 8.1% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jan 20
Virbac SA Provides Revenue Guidance for the Year 2022 Virbac SA provided revenue guidance for the year 2022. The company anticipates in 2022 a growth in revenue at constant rates and scope of between 5% and 8%. Tillkännagivande • Sep 14
Virbac SA (ENXTPA:VIRP) acquired an additional 15% stake in Centrovet group for $17.7 million. Virbac SA (ENXTPA:VIRP) acquired an additional 15% stake in Centrovet group for $17.7 million on September 13, 2021. Virbac’s stake increased to 66% post completion of the transaction. This transaction will have limited impact on the financial statements of Virbac.
Virbac SA (ENXTPA:VIRP) completed the acquisition of an additional 15% stake in Centrovet group on September 13, 2021. Tillkännagivande • Jul 07
Virbac SA Raises Revenue Guidance for 2021 Virbac SA raised revenue guidance for 2021. For the period, the company anticipate revenue growth at constant rates and scope between 10% and 14% (i.e. between 7% and 11% at constant rates and real perimeter). Upcoming Dividend • Jun 17
Upcoming dividend of €0.75 per share Eligible shareholders must have bought the stock before 23 June 2021. Payment date: 25 June 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.8%). Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improved over the past week After last week's 25% share price gain to €277, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 116% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €322 per share. Tillkännagivande • Apr 16
Virbac SA Revises Earnings Guidance for the Year 2021 Virbac SA revised earnings guidance for the year 2021. It currently anticipate revenue growth at constant rates and scope of between 6% and 10% (i.e. between 3% and 7% at constant rates and real perimeter), as well as a ratio of current operating profit, before depreciation of assets arising from acquisitions over revenue which should be between 12% and 14% at constant exchange rates. Reported Earnings • Mar 19
Full year 2020 earnings released: EPS €16.29 (vs €6.11 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €934.2m (flat on FY 2019). Net income: €137.5m (up 167% from FY 2019). Profit margin: 15% (up from 5.5% in FY 2019). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Mar 03
Virbac SA to Report Fiscal Year 2020 Results on Mar 17, 2021 Virbac SA announced that they will report fiscal year 2020 results After-Market on Mar 17, 2021 Is New 90 Day High Low • Feb 26
New 90-day low: €204 The company is down 4.0% from its price of €212 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €217 per share. Tillkännagivande • Feb 22
Algenex and Virbac Signs International Commercial Licensing Agreement for Crisbio-Based Vaccine in Major Swine Indication Algenex SL and Virbac announced that they have entered into an international licensing agreement for the development and commercialization of a CrisBio®-based vaccine in a major swine indication. The vaccine will be developed jointly and manufactured using CrisBio®, Algenex’ proprietary and patent protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors. CrisBio® represents a new paradigm in biologics production, offering a quick, linearly scalable solution to meet the global demand for recombinant protein production without significant capex investment. Algenex anticipates receiving European approval of the first veterinary vaccine produced using CrisBio in 2021. Is New 90 Day High Low • Jan 06
New 90-day high: €244 The company is up 21% from its price of €201 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €231 per share. Tillkännagivande • Dec 15
Virbac SA, Annual General Meeting, Jun 21, 2021 Virbac SA, Annual General Meeting, Jun 21, 2021. Is New 90 Day High Low • Dec 12
New 90-day high: €222 The company is up 23% from its price of €181 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €231 per share. Is New 90 Day High Low • Oct 15
New 90-day high: €220 The company is up 14% from its price of €194 on 17 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €200 per share. Reported Earnings • Sep 18
First half earnings released Over the last 12 months the company has reported total profits of €72.3m, up 110% from the prior year. Total revenue was €952.9m over the last 12 months, up 5.5% from the prior year. 
